PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE PATENT EXAMINING OPERATION

Applicant(s): Glen H. ERIKSON et al.

Serial No: 09/885,731

Group Art Unit: 1637

Filed: June 20, 2001

Examiner: S. Chunduru

Att. Docket No.: E1047/20056

Confirmation No.: 6800

For: NUCLEIC ACID MULTIPLEX FORMATION

RESUBMISSION OF APRIL 5, 2002 IDS

Commissioner for Patents Washington, DC 20231

Sir:

In accordance with Examiner's Chunduru's request to the undersigned by telephone earlier today, courtesy copies of the April 5, 2002 Information Disclosure Statement cover sheet, Transmittal Form, Form PTO-1449, date-stamped postcard receipt and the Rocher article are attached hereto. It was agreed that the Examiner will print and review a copy of (the relatively lengthy) U.S. Patent No. 6,312,925 from the PTO's patent database.

Respectfully submitted,

CAESAR, RIVISE, BERNSTEIN, COHEN & POKOTILOW, LTD.

January 14, 2002

Please charge or credit our Account No. 03-0075 as necessary to effect entry and/or ensure consideration of this submission. David M. Tener

Registration No. 37,054

Customer No. 03000

(215) 567-2010

Attorneys for Applicants

FACSIMILE TRANSMISSION CERTIFICATION

Ву__

I hereby certify that this correspondence re Application No. 09/885,731 is being transmitted via facsimile to Examiner S. Chunduru of Group Art Unit 1637 of the United States Patent and Trademark Office at (703) 746-7411 on this 14th day of January, 2003.

David M. Tener, Reg. No. 37,054

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE PATENT EXAMINING OPERATION

Applicant(s): Glen H. ERIKSON et al.

Serial No: 09/885,731

Group Art Unit:

Filed: June 20, 2001

Examiner:

Att. Docket No.: E1047/20056

Confirmation No.: 6800

For: NUCLEIC ACID MULTIPLEX FORMATION

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, DC 20231

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom. No representation is made that the reference(s) is/are prior art with respect to this application.

This Information Disclosure Statement is being filed within three months of the filing date of a national application other than a CPA under 37 CFR § 1.53(d), within three months of the date of entry of the national stage as set forth in 37 CFR § 1.491 in an international application, before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of an RCE under 37 CFR § 1.114. No certification or fee is required. 37 CFR § 1.97(b).

By_

Respectfully submitted,

CAESAR, RIVISE, BERNSTEIN,

COHEN & POKOTILOW, LTD.

April 5, 2002

Please charge or credit our Account No. 03-0075 as necessary to effect entry and/or ensure consideration of this submission.

David M. Tener

Registration No. 37,054 12th Floor, Seven Penn Center 1635 Market Street

Philadelphia, PA 19103-2212

(215) 567-2010

Attorneys for Applicant(s)

Customer No. 03000